You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Screen for hepatitis B virus in all cancer patients starting systemic treatment. Find out more about hepatitis B virus screening and management.

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

pegfilgrastim

( peg-fill-GRA-stim )
Other Name(s): Neulasta®; Lapelga™; Fulphila™; Ziextenzo®; Nyvepria™
Appearance: Clear, colourless solution for injection in a pre-filled syringe

Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.

Drug Monograph

Aug 2022
Table of Contents

Patient Info Sheet

Dec 2022

What it is used for

  • Pegfilgrastim is used to increase the growth of your white blood cells, which help your body fight against infection.
  • Pegfilgrastim is available as a biosimilar medication. See our biosimilar pamphlet for more information.


You might also be interested in

Funding & Reimbursement

Several payment sources exist for cancer drugs in Ontario, depending on the drug, disease indication, and how and where it is delivered.

View Funding & Reimbursement

Symptom Management

Many people living with cancer experience nausea, diarrhea and other symptoms from their treatment or disease.

View Symptom Management

Drug Safety and Administration

Find documents on drug safety and administration for healthcare providers, including calculations and recommendations.

View Drug Safety and Administration